{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:03:24Z","timestamp":1789131804674,"version":"build-2803163510"},"reference-count":89,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myeloproliferative neoplasms (MPNs) are the leading causes of unusual site thrombosis, affecting nearly 40% of individuals with conditions like Budd\u2013Chiari syndrome or portal vein thrombosis. Diagnosing MPNs in these cases is challenging because common indicators, such as spleen enlargement and elevated blood cell counts, can be obscured by portal hypertension or bleeding issues. Recent advancements in diagnostic tools have enhanced the accuracy of MPN diagnosis and classification. While bone marrow biopsies remain significant diagnostic criteria, molecular markers now play a pivotal role in both diagnosis and prognosis assessment. Hence, it is essential to initiate the diagnostic process for splanchnic vein thrombosis with a JAK2 V617F mutation screening, but a comprehensive approach is necessary. A multidisciplinary strategy is vital to accurately determine the specific subtype of MPNs, recommend additional tests, and propose the most effective treatment plan. Establishing specialized care pathways for patients with splanchnic vein thrombosis and underlying MPNs is crucial to tailor management approaches that reduce the risk of hematological outcomes and hepatic complications.<\/jats:p>","DOI":"10.3390\/ijms25031524","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:05:46Z","timestamp":1706241946000},"page":"1524","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights"],"prefix":"10.3390","volume":"25","author":[{"given":"Erika","family":"Morsia","sequence":"first","affiliation":[{"name":"Hematology Clinic, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"},{"name":"Department of Clinical and Molecular Sciences (DISCLIMO), Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-2969","authenticated-orcid":false,"given":"Elena","family":"Torre","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-9327","authenticated-orcid":false,"given":"Francesco","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences (DISCLIMO), Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"},{"name":"Clinic of Gastroenterology, Hepatology, and Emergency Digestive Endoscopy, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mor\u00e8","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"},{"name":"Department of Clinical and Molecular Sciences (DISCLIMO), Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4221-4125","authenticated-orcid":false,"given":"Antonella","family":"Poloni","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"},{"name":"Department of Clinical and Molecular Sciences (DISCLIMO), Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"},{"name":"Department of Clinical and Molecular Sciences (DISCLIMO), Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Rupoli","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"Special Report International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.patbio.2004.02.007","article-title":"A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP)","volume":"52","author":"Finazzi","year":"2004","journal-title":"Pathol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jth.14754","article-title":"Association between myelofibrosis and thromboembolism: A population-based retrospective cohort study","volume":"18","author":"Saliba","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MOH.0000000000000664","article-title":"Thrombosis in myeloproliferative neoplasms: Update in pathophysiology","volume":"28","author":"Reeves","year":"2021","journal-title":"Curr. Opin. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11739-010-0413-6","article-title":"Splanchnic vein thrombosis: Clinical presentation, risk factors and treatment","volume":"5","author":"Martinelli","year":"2010","journal-title":"Intern. Emerg. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1160\/TH07-08-0526","article-title":"Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis","volume":"99","author":"Dentali","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases","volume":"95","author":"Guglielmelli","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2022.08.003","article-title":"Splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"218","author":"Tremblay","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/j.1538-7836.2011.04484.x","article-title":"Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms","volume":"9","author":"Hoekstra","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00277-020-03965-z","article-title":"Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis","volume":"99","author":"Pereira","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2014.03.040","article-title":"Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases","volume":"134","author":"Dentali","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/VHRM.S310615","article-title":"Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary \u201cReal Life\u201d Experience","volume":"17","author":"Rupoli","year":"2021","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"a034876","DOI":"10.1101\/cshperspect.a034876","article-title":"The Molecular Genetics of Myeloproliferative Neoplasms","volume":"10","author":"Marneth","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2014-12-618074","article-title":"The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients","volume":"125","author":"Lau","year":"2015","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.hoc.2020.12.002","article-title":"Genetics of Myeloproliferative Neoplasms","volume":"35","author":"Szybinski","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1365-2141.2000.02030.x","article-title":"Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders","volume":"110","author":"Jensen","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2005.05.023","article-title":"Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils","volume":"42","author":"Falanga","year":"2005","journal-title":"Semin. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu\/BCAM","volume":"110","author":"Wautier","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1097\/HS9.0000000000000364","article-title":"Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis","volume":"4","author":"Guy","year":"2020","journal-title":"HemaSphere"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Farina, M., Bernardi, S., Polverelli, N., D\u2019adda, M., Malagola, M., Bosio, K., Re, F., Almici, C., Dunbar, A., and Levine, R.L. (2021). Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells, 10.","DOI":"10.3390\/cells10102764"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Morsia, E., Torre, E., Poloni, A., Olivieri, A., and Rupoli, S. (2022). Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094573"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjh.15010","article-title":"Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis","volume":"183","author":"Tefferi","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14728222.2021.1915992","article-title":"Myelofibrosis: Challenges for preclinical models and emerging therapeutic targets","volume":"25","author":"Morsia","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"874146","DOI":"10.1155\/2011\/874146","article-title":"Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms","volume":"2011","author":"Stein","year":"2011","journal-title":"Thrombosis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jceh.2021.11.003","article-title":"Portal Vein Thrombosis in Cirrhosis","volume":"12","author":"Shukla","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0035-1550439","article-title":"Splanchnic Vein Thrombosis","volume":"41","author":"Valla","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1538-7836.2011.04562.x","article-title":"Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"10","author":"Muus","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0002-9343(96)00351-8","article-title":"Inapparent polycythemia vera: An unrecognized diagnosis","volume":"102","author":"Lamy","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.24993","article-title":"Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases","volume":"93","author":"Lavu","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"Vannucchi","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: Molecular-driven diagnosis and long-term treatment","volume":"115","author":"Qi","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","volume":"2014","author":"Nangalia","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: A meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments","volume":"93","author":"Za","year":"2008","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ajh.26336","article-title":"Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"Fiorini","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: Treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","article-title":"JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: A meta-analysis","volume":"113","author":"Dentali","year":"2009","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease","volume":"8","author":"How","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: A study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/bs.ircmb.2021.02.009","article-title":"Lessons from mouse models of MPN","volume":"366","author":"Benlabiod","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","article-title":"JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis","volume":"211","author":"Soudet","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","article-title":"Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses","volume":"4","author":"Debureaux","year":"2020","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Galimberti, S., Balducci, S., Guerrini, F., Del Re, M., and Cacciola, R. (2022). Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. Diagnostics, 12.","DOI":"10.3390\/diagnostics12061305"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/ijlh.13560","article-title":"Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms","volume":"43","author":"Zheng","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","article-title":"JAK2(V617F): Prevalence in a large Chinese hospital population","volume":"109","author":"Xu","year":"2007","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1001\/jama.2010.853","article-title":"Primary myelofibrosis and the myeloproliferative neoplasms: The role of individual variation","volume":"303","author":"Stein","year":"2010","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2012-07-440487","article-title":"JAK2V617F activates Lu\/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1\/Akt pathway","volume":"121","author":"Cambot","year":"2013","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2018.05.007","article-title":"Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis","volume":"167","author":"Li","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Segura-D\u00edaz, A., Stuckey, R., Florido, Y., Gonz\u00e1lez-Mart\u00edn, J.M., L\u00f3pez-Rodr\u00edguez, J.F., S\u00e1nchez-Sosa, S., Gonz\u00e1lez-P\u00e9rez, E., Perdomo, M.N.S., Perera, M.d.M., and de la Iglesia, S. (2020). Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A\/TET2\/ASXL1 Mutations. Cancers, 12.","DOI":"10.3390\/cancers12040934"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"aan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020007488","article-title":"Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors","volume":"137","author":"Dunbar","year":"2021","journal-title":"Blood"},{"key":"ref_70","first-page":"e338","article-title":"Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?","volume":"5","author":"Soudet","year":"2021","journal-title":"TH Open Companion J. Thromb. Haemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1038\/s41467-021-26435-0","article-title":"Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils","volume":"12","author":"Kimishima","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/rccm.202210-1941OC","article-title":"Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study","volume":"208","author":"Montani","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-021-00470-y","article-title":"Mutations and thrombosis in essential thrombocythemia","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00277-023-05217-2","article-title":"Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort","volume":"102","author":"Cattaneo","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1538-7836.2010.03810.x","article-title":"New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis","volume":"8","author":"Colaizzo","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/leu.2013.337","article-title":"The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases","volume":"28","author":"Solary","year":"2014","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41591-022-01793-4","article-title":"In utero origin of myelofibrosis presenting in adult monozygotic twins","volume":"28","author":"Sousos","year":"2022","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2020.06.045","article-title":"Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis","volume":"74","author":"Magaz","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_83","first-page":"1447","article-title":"Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis","volume":"108","author":"Giugliano","year":"2023","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014Renewing consensus in portal hypertension","volume":"76","author":"Bosch","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2017.04.021","article-title":"Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study","volume":"67","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"Rossi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1182\/bloodadvances.2023012007","article-title":"Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?","volume":"7","author":"Barbui","year":"2023","journal-title":"Blood Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1524\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:38Z","timestamp":1760104178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":89,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25031524"],"URL":"https:\/\/doi.org\/10.3390\/ijms25031524","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}